Pacira BioSciences (PCRX) Current Leases (2019 - 2026)

Pacira BioSciences' Current Leases history runs 8 years deep, the most recent figure standing at $9.8 million for Q1 2026.

• On a quarterly basis, Current Leases rose 4.39% year-over-year to $9.8 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 4.39% increase from a year earlier, with the FY2025 full-year figure at $9.8 million, up 10.71% from the prior year.
• Current Leases was little changed at $9.8 million in Q1 2026 per PCRX's latest filing, from $9.8 million in the prior quarter.
• Across five years, Current Leases topped out at $9.8 million in Q4 2025 and bottomed at $8.0 million in Q1 2022.
• The 5-year median for Current Leases is $9.0 million (2024), against an average of $9.0 million.
• Across the five-year window, Current Leases surged 45.7% in 2022 and slipped 3.51% in 2023, its largest moves.
• Year by year, Current Leases stood at $9.1 million in 2022, then fell by 3.51% to $8.8 million in 2023, then advanced by 0.98% to $8.9 million in 2024, then rose by 10.71% to $9.8 million in 2025, then slipped by 0.21% to $9.8 million in 2026.
• Per Business Quant, the three latest PCRX Current Leases figures stand at $9.8 million (Q1 2026), $9.8 million (Q4 2025), and $9.7 million (Q3 2025).